Home » Expert Content » Biologics DevelopmentPage 2

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

BROWSE BY

TOPIC:






TYPE:





Novel Analytical Techniques For Monoclonal Antibodies

Summary: With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors. In this interview with Pharmaceutical Technology, Michael Sadick, Ph.D., and Dan Papa, Ph.D., of Catalent Biologics, talk about a new analytical testing panel…

read more

Antibody-Drug Conjugates – Where Are We Now?

Summary: In October 2015, during CPhI World Wide in Madrid, Spain, Oncology Tube from InPress Media Group, LLC. asked experts from Piramal Pharma Solutions, Carbogen Amcis and Catalent Biologics about challenges in the manufacturing of ADCs and how they see the market for ADCs evolve…

read more

The Ever-increasing Attraction of Biologics

Summary: The field of biologics promises targeted treatments for a range of conditions. For the promise of many of these therapies to become a reality, however, technological challenges must still be overcome, with many exciting novel treatments currently on, or making their way to, the market. This article published in Chemistry World discusses…

read more

Moving A Complex Protein From Development To Large-Scale Clinical Production

Summary: The number of more complex biopharmaceuticals in development continues to increase. These include molecules like virus-like particle vaccines, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, and more recently, numerous different multi-specific antibody platforms…

read more

Single-Use Bioreactors Pose E&L Challenges

Summary: Read the recent roundtable Q&A published in BioPharm International featuring biopharma executives discussing the challenges posed by single-use bioreactor bags in contributing to extractables and leachables in the biomanufacturing process…

read more

Accelerating Biologics And Biosimilar Development

Summary: Get to know how Catalent’s scientists have utilized ambr 15® as a micro-scale model for a synergistic clonal and process screen to identify the master cell bank candidates. Using this multi-layered approach, early in the development process significantly improves selection of top clones while shortening the overall timeline…

read more

Biosimilars: Getting Cheaper Biologics To The Market

Summary: The opportunity for new antibody biosmilar products is clear. By the end of this decade key patents currently protecting five monoclonal antibodies, each with sales in the neighborhood of a billion dollars a year will have expired, and companies are queuing up for a piece of the market…

read more

Biopharmaceuticals/ Biosimilars Roundtable, APR 2017

Summary: The biopharmaceutical market has seen incredible growth. American Pharmaceutical Review conducted industry round table with experts to share their opinion on the market drivers for growth, limiting factors and critical issues. Read the article to get insights on developing and marketing biopharmaceutical…

read more

Developing Site-Specifically Modified ADCs Using A Chemoenzymatic Approach

Summary: Antibody-drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development. This webinar hosted by Elsevier’s Drug Discovery Today presented novel protein modification platform and its application…

read more

Evolution Of Biomanufacturing Facilities

Summary: Advances in single-use bioreactor technologies offer rapid development pathways when combined with creative upstream process development strategies. When aggressive program timelines are required, the application of multiplexed conditions coupled with smart CMC decisions that maximize yields…

read more

Optimized Antibody Drug Conjugate Development

Summary: One of the current challenges with existing ADCs is the difficulty in creating conjugates with a uniform drug to antibody ratio and consistent payload placement on the antibody, both aspects which are paramount in creating consistent and predictable therapies…

read more